Identification of a novel RMST-ALK rearrangement in advanced lung adenocarcinoma and durable response to ceritinib: A case report

Next-generation sequencing technology has enabled the identification of fusion partners of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer, and various ALK fusion partners have been confirmed. Here, a novel rhabdomyosarcoma 2-associated transcript (RMST)-ALK rearrangement was identifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hui, Deng, Yixiao, Chen, Bin, Xiao, Yajie, Yang, Jie, Liu, Qionghui, Lin, Gengpeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376587/
https://www.ncbi.nlm.nih.gov/pubmed/35978810
http://dx.doi.org/10.3389/fonc.2022.913838
_version_ 1784768177603870720
author Li, Hui
Deng, Yixiao
Chen, Bin
Xiao, Yajie
Yang, Jie
Liu, Qionghui
Lin, Gengpeng
author_facet Li, Hui
Deng, Yixiao
Chen, Bin
Xiao, Yajie
Yang, Jie
Liu, Qionghui
Lin, Gengpeng
author_sort Li, Hui
collection PubMed
description Next-generation sequencing technology has enabled the identification of fusion partners of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer, and various ALK fusion partners have been confirmed. Here, a novel rhabdomyosarcoma 2-associated transcript (RMST)-ALK rearrangement was identified in an 80-year-old Chinese man with advanced lung adenocarcinoma. The patient was prescribed ceritinib and achieved a partial response, which has been sustained for more than 18 months. This is the first report of the RMST-ALK rearrangement, and we showed that a patient with lung adenocarcinoma carrying this rearrangement can benefit from ceritinib treatment; therefore, this is a significant finding in clinical practice.
format Online
Article
Text
id pubmed-9376587
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93765872022-08-16 Identification of a novel RMST-ALK rearrangement in advanced lung adenocarcinoma and durable response to ceritinib: A case report Li, Hui Deng, Yixiao Chen, Bin Xiao, Yajie Yang, Jie Liu, Qionghui Lin, Gengpeng Front Oncol Oncology Next-generation sequencing technology has enabled the identification of fusion partners of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer, and various ALK fusion partners have been confirmed. Here, a novel rhabdomyosarcoma 2-associated transcript (RMST)-ALK rearrangement was identified in an 80-year-old Chinese man with advanced lung adenocarcinoma. The patient was prescribed ceritinib and achieved a partial response, which has been sustained for more than 18 months. This is the first report of the RMST-ALK rearrangement, and we showed that a patient with lung adenocarcinoma carrying this rearrangement can benefit from ceritinib treatment; therefore, this is a significant finding in clinical practice. Frontiers Media S.A. 2022-08-01 /pmc/articles/PMC9376587/ /pubmed/35978810 http://dx.doi.org/10.3389/fonc.2022.913838 Text en Copyright © 2022 Li, Deng, Chen, Xiao, Yang, Liu and Lin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Hui
Deng, Yixiao
Chen, Bin
Xiao, Yajie
Yang, Jie
Liu, Qionghui
Lin, Gengpeng
Identification of a novel RMST-ALK rearrangement in advanced lung adenocarcinoma and durable response to ceritinib: A case report
title Identification of a novel RMST-ALK rearrangement in advanced lung adenocarcinoma and durable response to ceritinib: A case report
title_full Identification of a novel RMST-ALK rearrangement in advanced lung adenocarcinoma and durable response to ceritinib: A case report
title_fullStr Identification of a novel RMST-ALK rearrangement in advanced lung adenocarcinoma and durable response to ceritinib: A case report
title_full_unstemmed Identification of a novel RMST-ALK rearrangement in advanced lung adenocarcinoma and durable response to ceritinib: A case report
title_short Identification of a novel RMST-ALK rearrangement in advanced lung adenocarcinoma and durable response to ceritinib: A case report
title_sort identification of a novel rmst-alk rearrangement in advanced lung adenocarcinoma and durable response to ceritinib: a case report
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376587/
https://www.ncbi.nlm.nih.gov/pubmed/35978810
http://dx.doi.org/10.3389/fonc.2022.913838
work_keys_str_mv AT lihui identificationofanovelrmstalkrearrangementinadvancedlungadenocarcinomaanddurableresponsetoceritinibacasereport
AT dengyixiao identificationofanovelrmstalkrearrangementinadvancedlungadenocarcinomaanddurableresponsetoceritinibacasereport
AT chenbin identificationofanovelrmstalkrearrangementinadvancedlungadenocarcinomaanddurableresponsetoceritinibacasereport
AT xiaoyajie identificationofanovelrmstalkrearrangementinadvancedlungadenocarcinomaanddurableresponsetoceritinibacasereport
AT yangjie identificationofanovelrmstalkrearrangementinadvancedlungadenocarcinomaanddurableresponsetoceritinibacasereport
AT liuqionghui identificationofanovelrmstalkrearrangementinadvancedlungadenocarcinomaanddurableresponsetoceritinibacasereport
AT lingengpeng identificationofanovelrmstalkrearrangementinadvancedlungadenocarcinomaanddurableresponsetoceritinibacasereport

Ejemplares similares